Program
Niacinamide
Also written as “Nicotinamide” and “Nicotinamide (NAM)”.
Its studies are mostly in Anemia, Sickle Cell · Renal Insufficiency, Chronic, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| EpiDestiny | 11 open or running | phase 1since Aug 12, 2019 | Aug 12, 2019 | Oct 30, 2028phase 1 · NCT04055818 |
| Medice Arzneimittel Pütter GmbH & Co KG | 10 open or running | phase 2since Sep 10, 2010 | Sep 10, 2010 | none ahead |
| Metro International Biotech | 11 open or running | phase 1since Mar 11, 2025 | Mar 11, 2025 | Dec 2026phase 1 · NCT06882096 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 10, 2010First study: phase 2 study in Renal Insufficiency, ChronicNew to Medice Arzneimittel Pütter GmbH & Co KGMedice Arzneimittel Pütter GmbH & Co KG · NCT01200784 · 252 enrolled · Germany
- Aug 12, 2019EpiDestiny's first study: phase 1 study in Anemia, Sickle CellNew to EpiDestinyEpiDestiny · NCT04055818 · 20 planned · United States
- Mar 11, 2025Metro International Biotech's first study: phase 1 study in Healthy AdultsNew to Metro International BiotechMetro International Biotech · NCT06882096 · 32 planned · United States
Ahead
- Dec 2026Primary completion: phase 1 study in Healthy AdultsMetro International Biotech · NCT06882096
- Oct 30, 2028Primary completion: phase 1 study in Anemia, Sickle CellEpiDestiny · NCT04055818
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06882096Healthy Adults · United States | 1 | Recruiting | Metro International Biotech | Dec 2026 | 32 |
| NCT04055818Anemia, Sickle Cell · United States | 1 | Recruiting | EpiDestiny | Oct 30, 2028 | 20 |
| NCT01200784Renal Insufficiency, Chronic · Germany | 2 | Completed | Medice Arzneimittel Pütter GmbH & Co KG | Jun 2011 | 252 |
How it is read
Names in the registry
- “Nicotinamide”, 2 entries
- “Nicotinamide (NAM)”, 1 entry
Conditions, from the studies’ own filings
- Anemia, Sickle Cell, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.